KRIS SCALF: Open Payments
NPI 1376750109 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,019 in 64 payments from 17 companies in 2025. Trend: 2023 $1,646 · 2024 $1,037 · 2025 $1,019
Food & beverage: $1,019
| Company | Payments | Amount |
|---|---|---|
| MILLICENT US INC | 26 | $309 |
| Evofem Biosciences, Inc. | 7 | $121 |
| Sumitomo Pharma America, Inc. | 5 | $87 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $82 |
| Sage Therapeutics, LLC | 3 | $62 |
| Organon LLC | 3 | $60 |
| Exeltis, USA Inc. | 3 | $53 |
| Amgen Inc. | 3 | $46 |
| SHIELD THERAPEUTICS INC | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $25 |
Products named: FEMLYV, Phexxi, INTRAROSA, MYFEMBREE, ZURZUVAE, NEXPLANON, SLYND, EVENITY.
Industry payments across MO — which companies pay providers there.
